

# Anju Bhardwaj

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11288397/publications.pdf>

Version: 2024-02-01

17  
papers

1,399  
citations

516215

16  
h-index

887659

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

2108  
citing authors

#	ARTICLE	IF	CITATIONS
1	Update in recent clinical trials in heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 307-314.	0.8	2
2	Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. <i>Circulation</i> , 2017, 135, 116-127.	1.6	90
3	Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. <i>IJC Metabolic &amp; Endocrine</i> , 2014, 5, 11-18.	0.5	19
4	Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 250-261.	1.1	49
5	Influence of Transcatheter Aortic Valve Replacement Strategy and Valve Design on Stroke After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2101-2110.	1.2	123
6	Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 65-72.	1.9	167
7	Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. <i>European Journal of Heart Failure</i> , 2013, 15, 1157-1163.	2.9	102
8	Soluble Concentrations of the Interleukin Receptor Family Member ST2 and $\beta$ -Blocker Therapy in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 1206-1213.	1.6	116
9	Characterization and Prediction of Natriuretic Peptide $\alpha$ -Nonresponse During Heart Failure Management: Results From the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) Study. <i>Congestive Heart Failure</i> , 2013, 19, 135-142.	2.0	39
10	Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. <i>European Journal of Heart Failure</i> , 2013, 15, 342-351.	2.9	70
11	Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. <i>American Heart Journal</i> , 2012, 164, 793-799.e1.	1.2	54
12	Heart Failure Outcomes and Benefits of NT-proBNP-Guided Management in the Elderly: Results From the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. <i>Journal of Cardiac Failure</i> , 2012, 18, 626-634.	0.7	70
13	Use of Amino-Terminal Pro-B-Type Natriuretic Peptide to Guide Outpatient Therapy of Patients With Chronic Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1881-1889.	1.2	323
14	A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department. <i>American Heart Journal</i> , 2011, 162, 276-282.e1.	1.2	31
15	Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. <i>American Heart Journal</i> , 2010, 159, 532-538.e1.	1.2	58
16	ST2: a novel biomarker for heart failure. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 459-464.	1.5	60
17	Natriuretic Peptide-Guided Management of Acutely Destabilized Heart Failure. <i>Critical Pathways in Cardiology</i> , 2009, 8, 146-150.	0.2	26